Recent Trevena News
5/9/13 Trevena Inc. and Forest Laboratories Announce Development Collaboration For TRV027
The companies enter into a collaborative licensing option agreement for the development of TRV027 for Acute Heart Failure. Forest Laboratories also leads Trevena’s $60 Million Series C Funding Round. All existing investors participate in the round.
+ read more
5/1/13 Trevena’s President and CEO, Dr. Maxine Gowen presents at the Needham Healthcare Conference
Trevena’s President and CEO, Dr. Maxine Gowen presented an update of Trevena’s pipeline activities at the Twelfth Annual Needham Healthcare Conference on May 1st, 2013.
+ read more
3/18/13 Trevena presents first-in-man study results for mu-opioid biased ligand TRV130
Michael Lark, Chief Scientific Officer at Trevena, presents a poster at the 2013 American Academy of Neurology meeting on March 19th, 2013 describing the human safety and pharmacology of intravenous analgesic TRV130 in healthy volunteers. The data supports TRV130 progression to its next clinical study. Trevena is developing TRV130 for the intravenous treatment of acute moderate-to-severe post-operative pain.
+ read more
3/8/13 Trevena presents results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
Trevena presented a poster at the annual American College of Cardiology meeting on March 10th, 2013 describing the results of a Phase 2a invasive hemodynamics study of TRV027, a biased AT1R ligand in development for acute heart failure. The trial data supports advancement of TRV027 into further studies.
+ read more
1/23/13 JPET publication describes the discovery and activity of TRV130
Article illustrates how Trevena can translate a biased ligand hypothesis at the mu-opioid receptor into a differentiated therapeutic molecule.
+ read more
11/14/12 Trevena Completes FTIH Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain
TRV130 is generally well-tolerated and rapidly enters the CNS in healthy adult males.
+ read more
10/26/12 Trevena board member wins AAMC recognition award
Dr. Ralph Snyderman has won the 2012 David E. Rogers Award from the Association of American Medical College and the Robert Wood Johnson Foundation, for his contribution to improving the health and health care of the American people.
+ read more
10/10/12 Trevena, Inc. Founder Wins Nobel Chemistry Prize
The 2012 Nobel Prize for Chemistry has been awarded to Robert Lefkowitz and Brian Kobilka for their work on the G-protein coupled receptor system and its application in medical science.
+ read more
10/8/12 Trevena Completes Phase 2a Study of TRV027 in Patients with Advanced Heart Failure
TRV027 improves hemodynamics and is well-tolerated in patients with stable advanced heart failure, supporting advancement into a Phase 2b study in ADHF.
+ read more
9/4/12 TRV027 shows cardiac and renal benefits in dog heart failure model in combination with furosemide
A Mayo Clinic animal pharmacology study of TRV027, a Trevena ß-arrestin biased ligand at the Angiotensin II Type I Receptor, was published on-line in Circulation Heart Failure on August 13th, 2012. The findings indicate that TRV027 may work synergistically with loop diuretics like furosemide, which are current standard of care for treating acute heart failure.
+ read more
9/3/12 ß-arrestin-biased AT1R promotes cardiac cell survival during acute cardiac injury
A pharmacology study of TRV120023, a ß-arrestin biased AT1R ligand from Trevena, conducted by Duke scientists in an animal cardiac ischemia model was published on-line in the American Journal of Physiology on August 10th, 2012. This work suggests that the related biased AT1R ligand, TRV027, may protect cardiac function during acute heart failure.
+ read more
Copyright © Trevena, Inc.